Targeting sphingolipid metabolism to inhibit insulin-like growth factor signaling-driven glioma growth

Background Insulin-like growth factor (IGF) signaling drives progression of glioblastoma (GBM), the most aggressive brain cancer. While sphingolipid metabolism is implicated in gliomagenesis, the mechanism by which it regulates GBM growth and therapy response is poorly understood. Methods Through bioinformatic analyses of human gliomas, we identified sphingolipid metabolism genes with potential functional significance in glioma. Using patient-derived cells, a Drosophila glioma model, and xenograft mouse models, we investigated the functional role of Dihydroceramide desaturase 1 (DEGS1). Lipidomics profiling and RNA sequencing were performed in patient-derived cells to reveal the mechanism by which DEGS1 regulates glioma growth. Additionally, we tested the effect of a DEGS1 inhibitor on GBM cell growth and their resistance to IGF1R-targeted therapy. Results Our data demonstrate that the expression of sphingolipid metabolism gene DEGS1 is associated with aggressive glioma biomarkers and worse patient survival. DEGS1 is required for glioma growth in patient-derived cells, a Drosophila glioma model, and xenograft mouse models. Lipidomics profiling reveals that DEGS1 deficiency results in reduced ceramides and complex sphingolipids and accumulation of their precursors. Disrupted sphingolipid homeostasis impairs lipid raft biogenesis and lipid raft-associated IGF signaling. Targeting DEGS1 decreases GBM cell growth and their resistance to IGF1R inhibition. Conclusions These findings establish that targeting DEGS1-regulated sphingolipid metabolism is a viable avenue to inhibit IGF signaling-driven GBM growth.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2026-11-19
DOI
https://doi.org/10.1093/neuonc/noag221
Primary Topic
Sphingolipid Metabolism and Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting sphingolipid metabolism to inhibit insulin-like growth factor signaling-driven glioma growth

Peikun Liu, Xi Huang, Hongyu Zhao, Siyi Wanggou et al.
Neuro-Oncology
Sphingolipid Metabolism and Signaling
article

Targeting sphingolipid metabolism to inhibit insulin-like growth factor signaling-driven glioma growth

Peikun Liu, Xi Huang, Hongyu Zhao, Siyi Wanggou, 王利霞, Yu Shi, Shunjin Xia, Qi Yang, Zhichuan Sun
article en

Abstract

Background Insulin-like growth factor (IGF) signaling drives progression of glioblastoma (GBM), the most aggressive brain cancer. While sphingolipid metabolism is implicated in gliomagenesis, the mechanism by which it regulates GBM growth and therapy response is poorly understood. Methods Through bioinformatic analyses of human gliomas, we identified sphingolipid metabolism genes with potential functional significance in glioma. Using patient-derived cells, a Drosophila glioma model, and xenograft mouse models, we investigated the functional role of Dihydroceramide desaturase 1 (DEGS1). Lipidomics profiling and RNA sequencing were performed in patient-derived cells to reveal the mechanism by which DEGS1 regulates glioma growth. Additionally, we tested the effect of a DEGS1 inhibitor on GBM cell growth and their resistance to IGF1R-targeted therapy. Results Our data demonstrate that the expression of sphingolipid metabolism gene DEGS1 is associated with aggressive glioma biomarkers and worse patient survival. DEGS1 is required for glioma growth in patient-derived cells, a Drosophila glioma model, and xenograft mouse models. Lipidomics profiling reveals that DEGS1 deficiency results in reduced ceramides and complex sphingolipids and accumulation of their precursors. Disrupted sphingolipid homeostasis impairs lipid raft biogenesis and lipid raft-associated IGF signaling. Targeting DEGS1 decreases GBM cell growth and their resistance to IGF1R inhibition. Conclusions These findings establish that targeting DEGS1-regulated sphingolipid metabolism is a viable avenue to inhibit IGF signaling-driven GBM growth.

Neuro-Oncology
Central South University (CN), University of Toronto (CA), Hospital for Sick Children (CA), Xiangya Hospital Central South University (CN)
Sphingolipid Metabolism and Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon